Nefoxef (Fexofenadine Hydrochloride)

Fexofenadine acts as a selective peripheral H1‑receptor antagonist. By binding to H1 receptors on mast cells and other tissues, it blocks histamine from triggering the cascade that leads to vasodilation, increased vascular permeability, and nerve stimulation, thereby mitigating the typical signs of an allergic reaction.

The appropriate dose of Nefoxef is determined by the prescribing healthcare professional based on the patient’s age, weight, renal function, and specific indication. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for fexofenadine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting Nefoxef.

To request Nefoxef, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nefoxef (fexofenadine) is a second‑generation H1 antihistamine, offering effective allergy relief with minimal sedation compared with first‑generation agents like diphenhydramine. Its peripheral selectivity reduces central nervous system effects, making it suitable for patients who need to avoid drowsiness.

Nefoxef should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Nefoxef is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed. For optimal absorption, it can be taken with or without food, but patients should avoid taking it simultaneously with antacids or fruit juices that may interfere with absorption.

While rare, serious adverse reactions to Nefoxef can include anaphylaxis, angioedema, severe skin reactions such as Stevens‑Johnson syndrome, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like difficulty breathing, swelling of the face or throat, or unexplained heart palpitations.

Nefoxef is contraindicated in individuals with known hypersensitivity to fexofenadine or any of its excipients. Patients taking strong CYP3A4 inhibitors such as ketoconazole, erythromycin, or ritonavir should avoid co‑administration due to the risk of elevated drug levels.